• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
      • 7.1.1.1 2000
      • 7.1.1.2 2001
      • 7.1.1.3 2002
      • 7.1.1.4 2003
      • 7.1.1.5 2004
      • 7.1.1.6 2005
      • 7.1.1.7 2006
      • 7.1.1.8 2007
      • 7.1.1.9 2008
    • 7.1.2 Health
  • 7.2 Photos & Logos

Merz Pharmaceuticals launches AXURA® for the treatment of Alzheimer’s disease

Frankfurt am Main, 01.08.2002

Alzheimer’s disease is the most common form of dementia. Late-stage patients represent a substantial proportion of the total Alzheimer’s population. Despite a stable prevalence rate, the 8.3 million Alzheimer’s disease patients in 1998 in the U.S., Japan and Europe (Germany, UK, France, Italy, Spain) is expected to increase to 10.2 million by 2008, due to the growing number of senior citizens in these countries. According to the Alzheimer’s Association, it is projected that by 2050 more than 14 million people may develop Alzheimer’s disease in the U.S. alone.

Merz has received approval for AXURA® for the treatment of moderately severe and severe Alzheimer’s disease from the European Commission. The NMDA receptor antagonists memantine demonstrates clinically significant efficacy in patients with moderately severe and severe Alzheimer’s disease. Starting with Germany in August 2002, AXURA® will become available in several European countries and other selected territories of the world.

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s